公司研发进展 - 公司召开研发更新电话会议，重点介绍其潜在同类最优、高选择性口服KRAS G12D开关抑制剂VS-7375 [1][2] - 会议分享了Target-D临床开发项目的进展，包括来自Target-D 101剂量递增和剂量扩展试验的初步数据 [2] - 公司已发布详细新闻稿和演示文稿，可供投资者查阅 [2] 产品管线 - 核心在研产品为VS-7375，是一种针对KRAS G12D突变的口服开关抑制剂 [2]

Verastem (NasdaqCM:VSTM) Update / briefing June 23, 2026 04:30 PM ET Speaker11 Afternoon. Welcome to Verastem Oncology's VS-7375 R&D update conference call. My name is Tawanda, and I will be your call operator today. Please note this event is being recorded. All participants will be in a listen- only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Viana, Senior Vice President of Corporate Communications, Investor Relations, and Patien ...

VS-7375: Potential Best-in-Class KRAS G12D (ON/OFF) Inhibitor FORWARD-LOOKING STATEMENTS R&D Update Call J u n e 2 3 , 2 0 2 6 Disclaimers This presentation includes forward-looking statements about, among other things, Verastem Oncology's (the "Company") programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirst ...